Repare Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Repare Therapeutics generated cash of -$127,158,000, which is less than the previous year. Cash used in financing activities reached the amount of $842,000 last year. Net change in cash is therefore -$48,253,000.
Cash Flow
| 2017 | -6.00M | -1.15M | 30.45M |
|---|---|---|---|
| 2018 | -12.61M | -583K | 0 |
| 2019 | -18.42M | -1.30M | 103.24M |
| 2020 | -6.08M | -9.76M | 247.84M |
| 2021 | -85.79M | -1.67M | 95.55M |
| 2022 | 322K | -175.77M | 880K |
| 2023 | -127.15M | 78.04M | 842K |
RPTX Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 159.52M | 334.42M | 326.39M | 95.00M | 10.92M | 24.38M | 1.08M |
Operating activities | |||||||
Net income | -93.79M | -29.04M | -106.90M | -53.41M | -27.21M | -14.28M | -7.79M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 1.95M | 1.97M | 1.47M | 897K | 605K | 407K | 102K |
Stock-based compensation expense | 25.06M | 19.69M | 12.82M | 2.53M | 511K | 0 | 34K |
| Deferred income tax benefit | 25.06M | 19.69M | 12.82M | 2.53M | 511K | 0 | 34K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 0 | -1.52M | 2.99M | -2.94M | -1.91M | 0 | -609K |
Inventories | 0 | 0 | -2.99M | 2.94M | 1.91M | 0 | 0 |
Accounts payable | 1.93M | -1.34M | 152K | 17K | 833K | 10K | 730K |
Cash generated by operating activities | -127.15M | 322K | -85.79M | -6.08M | -18.42M | -12.61M | -6.00M |
Investing activities | |||||||
Purchases Of Investments | -179.02M | -256.57M | -7.47M | -7.52M | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -1.93M | -602K | -1.69M | -2.23M | -1.30M | -583K | -1.15M |
Acquisitions Net | 0 | 175.17M | 40K | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 78.04M | -175.77M | -1.67M | -9.76M | -1.30M | -583K | -1.15M |
Financing activities | |||||||
Common Stock Issued | 842K | 880K | 95.55M | 232.04M | 103.24M | 0 | 28.95M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 689K | 433K | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 | 1.5M |
Cash used in financing activities | 842K | 880K | 95.55M | 247.84M | 103.24M | 0 | 30.45M |
Net Change In Cash | -48.25M | -174.90M | 8.03M | 231.39M | 84.07M | -13.46M | 23.30M |
Cash at end of period | 111.26M | 159.52M | 334.42M | 326.39M | 95.00M | 10.92M | 24.38M |
| Data source | Data source | Data source | Data source |